¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Runyon group III mycobacteria"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • group-specific antigen
    ¹«¸®Æ¯ÀÌÇ׿ø, ±ºÆ¯ÀÌÇ׿ø
  • high risk group
    °íÀ§Ç豺
  • haptenic group
    ºÒ¿ÏÀüÇ׿ø±º, ÇÕÅÙ±º
  • linkage group
    ¿¬°ü±º
  • low risk group
    ÀúÀ§Ç豺
  • methyl group
    ¸ÞÆ¿±â
  • osmophore group
    ¹ßÇâ´Ü(Û¡úÅÓ¥)
  • prosthetic group
    1. º¸°áºÐÀÚ´Ü 2. º¸°á¿øÀÚ´Ü
  • Rh blood group system
    RhÇ÷¾×Çüü°è
  • soluble group
    °¡¿ëÇØ±º
  • self-help group
    ÀÚ°¡µµ¿òÁý´Ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù
  • group hospital
    º´¿øÁ¶ÇÕ
  • group medicine
    Áý´ÜÁø·á, Çùµ¿Áø·á
  • group practice
    Áý´Ü°³¾÷
  • group psychotherapy
    Áý´ÜÁ¤½Å¿ä¹ý
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢
  • group fascicular repair
    ½Å°æ¼¶À¯´Ù¹ß±ººÀÇÕ(¹ý)
  • group reference value
    Áý´Ü±âÁØÄ¡
  • haptenic group
    ºÒ¿ÏÀüÇ׿ø±º, ÇÕÅÙ±º
  • high risk group
    °íÀ§Çèµµ±º
  • index group
    ÃʹßȯÀÚ±º
  • labile methyl group
    ºÒ¾ÈÁ¤¸ÞÆ¿±â
  • linkage group
    ¿¬°ü±º
  • marathon group
    ¸¶¶óÅæÁý´Ü
  • methyl group
    ¸ÞÆ¿±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Rh blood group system
    Rh Ç÷¾×Çü±º
  • amino group
    ¾Æ¹Ì³ë±â(¡­Ðñ).
  • analytic group psychotherapy
    ºÐ¼®Àû Áý´Ü Á¤½ÅÄ¡·á
  • anterior sinus group
    ÀüºÎºñµ¿±º
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ).
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù.
  • group
    ±º
  • group I fiber
    Á¦¥°¤Çí·A(ð¯ìéÏØàéë«).
  • group I fiber
    Á¦¥°±º¼¶À¯(ð¯ìéÏØàéë«).
  • group II fiber
    Á¦¥±¤Çí·A.
  • group II fiber
    Á¦¥± ±º¼¶À¯(ÏØàéë«).
  • group IV fiber
    Á¦¥³¤Çí·A.
  • group IV fiber
    Á¦¥³±º¼¶À¯(ÏØàéë«).
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • blood group incompatibility
    Ç÷¾×ÇüºÎÀûÇÕ.
  • blood group mucoids
    Ç÷¾×ÇüÁ¡Áú.
  • blood group polysaccharide
    Ç÷¾×Çü´Ù´ç·ù(¡­ÒýӨ׾).
  • blood group polysaccharide
    È­Ç÷¾×Çü´Ù´ç·ù(¡­ÒýӨ׾).
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú.
  • blood group system
    Ç÷¾×Çü±º
  • borderline group
    °æ°è±º(ÌÑÍ£ÏØ).
  • carbohydrate, group-specfic C
    ±ºÆ¯ÀÌ C ź¼öÈ­¹°
  • coliform group
    ´ëÀå±Õ±º
  • commutative group
    °¡È¯±º(˧̷˴).
  • commutator group
    ±³È¯ÀÚ±º(ÊÙË´).
  • complementation group
    »óº¸¼º Áý´Ü
  • complementophil group
    º¸Ã¼Ä£È­±â.
  • control group
    ´ëÁ¶±º(ÓßðÎÏÛ)
  • control group
    ´ëÁ¶±º(ËÀ̡˴).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ)
  • functional group isomer
    ÀÛ¿ë±â(íÂéÄÐñ) À̼ºÃ¼(ì¶àõô÷)
  • glucosyl group
    ±Û·çÄڽDZâ(Ðñ)
  • glycoaldehyde group
    ±Û¶óÀÌÄھ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycolaldehyde group
    ±Û¶óÀÌÄݾ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycoloyl group
    ±Û¶óÀÌÄÚ·ÎÀϱâ(Ðñ)
  • glycolyl group
    ±Û¶óÀÌÄÚ¸±±â(Ðñ)
  • glycosyl group
    ±Û¶óÀÌÄڽDZâ(Ðñ)
  • Gm group
    Gm ±â(Ðñ)
  • group specificity
    ±â(Ðñ) ƯÀ̼º(÷åì¶àõ)
  • group transfer reaction
    ¿øÀÚ´Ü ÀüÀÌ ¹ÝÀÀ(ê«í­Ó¥ï®ì¹Úãëë)
  • group transfer potential
    ¿øÀÚ´Ü ÀüÀÌ ÀüÀ§(ê«í­Ó¥ï®ì¹Úãëë)
  • group translocation
    ¹«¸® ÀüÀ§(ï®êÈ)
  • guanidinium group
    ±¸¾Æ´Ïµð´Ï¿ò±â(Ðñ)
  • guanidino group
    ±¸¾Æ´Ïµð³ë±â(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
DRG diagnosis-related group; Division of Research Grants [NIH}; dorsal respiratory group; dorsal root ga...
GS gallstone; Gardner syndrome; gastric shield; general surgery; gestational score; Gilbert syndrome; g...
GT gait training; galactosyl transferase; gastrostomy; generation time; genetic therapy; gingiva treatm...
MN a blood group in the MNSs blood group system; malignant nephrosclerosis; Master of Nursing; meganewt...
GTN   - Stages of GTN(FIGO, WHO)
    1. Stage O; Molar Pregnancy(H-Mole...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CTAP III Connective tissue activating peptide III
endo III Endonuclease III
Exo III Exonuclease III
GSD III Glycogen storage disease type III
HTLV III Human T Cell Lymphotropic Virus Type III
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Q : Àü±â·®ÀÇ coulombÀÇ ±âÈ£.

    Q blood group system

    Å¥½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. µÅÁö Ç÷ûÀÇ ¾î¶² °Í¿¡ Á¸ÀçÇÏ´Â Ç× Q ÀÀÁý¼Ò¸¦ °¡ÇßÀ» ¶§ ÀÀÁýÇϴ°¡ ÇÏÁö ¾Ê´Â°¡¿¡ µû¶ó Ç÷¾×À» ºÐ·ùÇÏ´Â °ÍÀÌ´Ù. Ç× QÀÀÁý¼Ò´Â P½Ä Ç÷¾×ÇüÀÇ Ç× P ÀÀÁý¼Ò¿Í µ¿ÀÏÇÑ °ÍÀ̶ó´Â Çм³µµ ÀÖ´Ù.
  • Rh blood group
    Rh Ç÷¾×Çü, ¾Æ¸£ ¿¡ÀÌÄ¡½Ä Ç÷¾×Çü
    1940³â ¹Ì±¹ÀÇ K. ¶õÆ®½´Å¸ÀÌ³Ê µî¿¡ ÀÇÇÏ¿© ¹ß°ßµÈ ÀÓ»óÀûÀ¸·Î ¾ÆÁÖ Áß¿äÇÑ Ç÷¾×Çü. Rh¶ó´Â °ÍÀº, óÀ½¿¡ À̰ÍÀ» °ËÃâÇϴµ¥ ÇÊ¿äÇÑ Ç×Ç÷ûÀ» ¾ò±â À§ÇÏ¿© »ç¿ëÇÑ ¸é¿ª µ¿¹°ÀÎ ºÓÀºÅпø¼þÀÌ
  • S-blood group
    ¿¡½º½Ä Ç÷¾×Çü
    ABO½Ä Ç÷¾×Çü°ú °ü°è ÀÖ´Â Ç÷¾×Çü. Ç÷¾×ÀÇ ºÐºñÇü, ºñºÐºñÇüÀÇ ºÐ·ù¶ó°í Çϸç, 1932³â µ¶ÀÏÀÇ F. ½ÃÇÁ°¡ ¹ß°ßÇÏ¿´´Ù. ABO½Ä Ç÷¾×Çü¿¡ ¼ÓÇÏ´Â Ç׿ø ¹°Áú
  • zymophore group
    È¿¼ÒÀÛ¿ëÁ·
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
congenital antithrombin III deficiency Antithrombin III is a protein which stimulates the removal of blood clots in the bloodstream. Small blood clots form normally within the bloodstream, but are normally dissolved via the bodys antithrombin III. The deficiency of antithrombin III will result in an increased risk for blood clot formation causing organ damage. This is an inherited as a autosomal dominant trait.
Inheritance: autosomal dominant.
(27 Sep 1997)
connective tissue activating peptide III Cytokine, produced from platelet basic protein, that acts as a growth factor.
(18 Nov 1997)
mycinamicin III O-methyltransferase <enzyme> Catalyses the incorporation of the methyl group of s-adenosyl-l-methionine at the 3'' position of mycinamicin III; from micromonospora griseorubida; genbank d16097
Registry number: EC 2.1.1.-
Synonym: mycf gene product, miii o-mtase
(26 Jun 1999)
cranial mononeuropathy III (compression type) A disorder involving vision changes and eyelid drooping associated with a decreased functioning of cranial nerve III. Damage is usually caused by compression of the nerves from localised lesions or a swelling in the area of the nerve.
Examples include cerebral aneurysms and tumours Symptoms include a drooping eyelid and double vision.
(diabetic type) A disorder involving vision changes and eyelid drooping associated with a decreased functioning of cranial nerve III as a complication of diabetes.
Symptoms include a drooping eyelid and double vision. Good control of blood sugars can reduce the incidence of this complication.
(27 Sep 1997)
cranial nerve III <anatomy, nerve> The occulomotor nerve is responsible for motor enervation of upper eyelid muscle, extraocular muscle and pupillary muscle.
Lesions of the oculomotor nerve results in ptosis (dropping eyelid), deviation of the eyeball outward, double vision and a dilated pupil.
Synonym: cranial nerve III.
(27 Sep 1997)
processus styloideus ossis metacarpalis III A pointed projection from the dorsolateral angle of the base of the third metacarpal bone; it sometimes exists as a separate ossicle.
Synonym: processus styloideus ossis metacarpalis III.
(05 Mar 2000)
protoporphyrinogen type III The immediate precursor of protoporphyrin III in haem biosynthesis; elevated in cases of variegate porphyria.
(05 Mar 2000)
protoporphyrinogen type III oxidase A mitochondrial enzyme that uses O2 to convert protoporphyrinogen type III to protoporphyrin type III in haem biosynthesis; a deficiency of this enzyme is associated with variegate porphyria.
(05 Mar 2000)
protoporphyrin type III 2,7,12,18-Tetramethyl-3,8-divinylporphin-13,17dipropionic acid;the principal protoporphyrin found in nature (one of 15 possible isomers), characterised by the presence of 4 methyl groups, 2 vinyl groups, and 2 propionic acid side chains; a porphyrin derivative that, with iron, forms the haem of haemoglobin and the prosthetic groups of myoglobin, catalase, cytochromes, etc.
(05 Mar 2000)
Hind III <enzyme, molecular biology> Commonly used type II restriction endonuclease isolated from Haemophilus influenzae, it cleaves the sequence AAGCTT between the two As thus generating sticky ends.
(18 Nov 1997)
HTLV-III <abbreviation> Human T-cell lymphotropic virus type III.
See: human immunodeficiency virus.
(05 Mar 2000)
hyperlipoproteinaemia type III A rather uncommon form of familial hyperlipaemia characterised by the presence of lipoproteins of abnormal composition. The main abnormal lipoproteins are called beta-vldl and have a different apoprotein content and a higher proportion of cholesterol relative to triglyceride than normal vldl.
(12 Dec 1998)
NADH-Fe(III)EDTA oxidoreductase <enzyme> From cryptococcus albidus; catalyses the formation of nad+ and fe(ii)edta from NADH and fe(iii)edta; forms ethylene from 2-oxo-4-methylthiobutyric acid
Registry number: EC 1.6.99.-
(26 Jun 1999)
Sudan III A red stain, (C6H5)N==N(C6H4)N==N(C10H6)OH, used for neutral fat in histologic technique; it also stains the fatty envelope of the tubercle bacillus.
Synonym: Sudan red III.
(05 Mar 2000)
Sudan red III A red stain, (C6H5)N==N(C6H4)N==N(C10H6)OH, used for neutral fat in histologic technique; it also stains the fatty envelope of the tubercle bacillus.
Synonym: Sudan red III.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • habitat group
    »ýÅ·ù(¼­½Ä ȯ°æÀ» °°ÀÌ ÇÏ´Â µ¿½Ä¹°);(¹Ú¹°°ü¿¡ Àü½ÃµÈ)»ý¹° ȯ°æ ¸ðÇü
  • income group
    »çȸ ¼ÒµæÃþ(µ¿ÀÏ ¼Òµæ¼¼¾×Áý´Ü)
  • informal group
    (»çȸ)ºñ°ø½ÄÀû Áý´Ü(°üû°øÀåµî¿¡¼­ÀÇ)
  • interested group
    (»çȸ)ÀÌÀͰøµ¿Ã¼;°øÅëÀÌÇØ´Üü(±¹°¡ Á¤´çŬ·´µî)
  • minority group
    ¼Ò¼ö¹ÎÁ·(Çѳª¶óÀÇ)
  • peer group
    µ¿·á Áý´Ü;µ¿¹è Áý´Ü
  • pressure group
    ¾Ð·Â ´Üü
  • primary group
    Á¦ ÀÏÂ÷ Áý´Ü(°¡Á¤,Ä£±¸ µî)
  • rape group
    ÅäÀÇ(Åä·Ð)±×·ì
  • reference group
    ÁذŠÁý´Ü(°³ÀÎÀÌ ÀÚ±â ŵµ.ÆÇ´ÜÀÇ ±âÁØÀ¸·Î ¿©±â´Â ƯÁ¤ Áý´Ü)
  • splinter group
    ºÐÆÄ;¼Ò¼öÆÄ
  • tail group
    TAIL UNIT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á